🔺 What to do when markets are at an all-time high? Find smart bargains, like these.See Undervalued Stocks

Vaxxinity Inc (VAXX)

OTC Markets
Currency in USD
0.0001
0.0000(0.00%)
Closed
VAXX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
0.00010.0600
52 wk Range
0.00011.1000
Key Statistics
Edit
Prev. Close
0.0001
Open
0.06
Day's Range
0.0001-0.06
52 wk Range
0.0001-1.1
Volume
103.85K
Average Volume (3m)
20.68K
1-Year Change
-99.99%
Book Value / Share
0.11
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VAXX Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Vaxxinity Inc Company Profile

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Compare VAXX to Peers and Sector

Metrics to compare
VAXX
Peers
Sector
Relationship
P/E Ratio
0.0x−3.0x−0.6x
PEG Ratio
0.00−0.040.00
Price/Book
0.0x1.8x2.6x
Price / LTM Sales
-28.0x3.2x
Upside (Analyst Target)
-190.1%46.2%
Fair Value Upside
Unlock13.2%7.0%Unlock

FAQ

What Is the Vaxxinity (VAXX) Stock Price Today?

The Vaxxinity stock price today is 0.0001

What Stock Exchange Does Vaxxinity Trade On?

Vaxxinity is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Vaxxinity?

The stock symbol for Vaxxinity is "VAXX."

What Is the Vaxxinity Market Cap?

As of today, Vaxxinity market cap is 12.67K.

What is Vaxxinity Earnings Per Share?

The Vaxxinity EPS is -0.45.

What Is the Next Vaxxinity Earnings Date?

Vaxxinity will release its next earnings report on Mar 31, 2025.

From a Technical Analysis Perspective, Is VAXX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.